Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Adaptive Symptom Self-Management Immunotherapy Study

NCT05715255 · View on ClinicalTrials.gov ↗

Study Summary

The use of immune checkpoint inhibitors (ICIs), alone or in combination with other cancer treatments is increasing dramatically with immune-related adverse events (irAEs) common (90%) during ICI treatment. Most irAEs are symptomatic and symptom self-management with timely reporting of moderate or severe symptoms to health care providers (HCPs) may reduce irAE severity by early recognition and management, resulting in fewer treatment interruptions and unscheduled health services.

Interventions

  • BEHAVIORAL Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C)
  • BEHAVIORAL Active control comparator

Study Locations (3)

Arizona

  • Valleywise Health Medical Center — Phoenix
  • University of Arizona Cancer Center — Tucson

Michigan

  • University of Michigan — Ann Arbor

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2023-05-08
Est. Completion 2027-04-30
Phase NA

Sponsor

University of Arizona

379 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05715255

The ClinicalTrials.gov registry entry for NCT05715255 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 379 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions — of which Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05715255 reports 3 study locations spanning 2 distinct geographic areas — top geographies include Arizona, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05715255 about?

NCT05715255 is a clinical study titled "Adaptive Symptom Self-Management Immunotherapy Study". The use of immune checkpoint inhibitors (ICIs), alone or in combination with other cancer treatments is increasing dramatically with immune-related adverse events (irAEs) common (90%) during ICI treatment. Most irAEs are symptomatic and symptom self-management with timely reporting of moderate or se...

What is the current status of trial NCT05715255?

This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2023-05-08. Estimated completion is 2027-04-30.

What conditions does trial NCT05715255 study?

This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Colon Cancer, Skin Cancer, Rectum Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05715255?

The interventions under investigation include: Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C) (BEHAVIORAL), Active control comparator (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05715255?

This trial is sponsored by University of Arizona, which has 379 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05715255 being conducted?

This trial has 3 study locations across Arizona, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial